Delivery Order SPE2DB22D2206-SPE2DB25FKC99
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a ceiling value of $2,761.55 and an ultimate completion date of September 29, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $4,698.42. This non-competitive delivery order represents a firm fixed price transaction with a completion date of September 12, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 30 mg capsules (100-count) with a contract value of $2,117.56 and completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,066.12 and an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,413.54 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Vyvanse 30 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 5, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Vyvanse 30 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $1,337.75. This non-set-aside award represents a single delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99 billion prime vendor agreement designated SPE2DX and extending through December 2026. The...
- The Defense Logistics Agency awarded a $15,814.20 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 10 mg capsules (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 26, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Vyvanse 50 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $1,891.07. This is a competitively awarded, non-set-aside delivery order with an ultimate completion date of September 10, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) valued at $1,783.60 with a firm fixed price structure. This competitively awarded, non-set-aside contract is a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) valued at $12,128.78 under firm fixed-price terms. This non-set-aside, competitively awarded delivery order represents a continuation of pharmaceutical procurement through the federal medical supply chain, with performance based in Conshohocken, Pennsylvania, and completion scheduled for September 25, 2025. AmerisourceBergen Drug...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKC99Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $5,369.39 and an ultimate completion date of September 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement and is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The performance location for this order is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. As the prime contractor on this delivery order, the company fulfills DLA's requirement for pharmaceutical products supporting Defense Health Agency operations and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of medications, medical devices, and specialized healthcare commodities across multiple therapeutic domains through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.4k | 9/26/25 |